阿斯利康第二季度营收同比增长12%至144.6亿美元,超出分析师预期的141.5亿美元,核心每股收益同比增长10%至2.17美元,符合市场预期。公司股价因此上涨超过3.5%,达到74.35美元。CEO Pascal Soriot表示,今年上半年收入增长势头持续强劲,并且在过去数周内有12项关键三期临床测试取得积极结果,包括Baxdrostat、Gefurulimab及Tagrisso等药物。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.